Intercell Ag

Valneva Austria Gmbh

Christoph Klade

Wolfgang Zauner

Oresta Vytvytska

Andreas Meinke

Claire M Fraser

Eszter Nagy

Tamas Henics

Thomas Weichhart

Steven Gill

Martin Hafner

Agnieszka Dryla

Hildegard Etz

Duc Bui Minh

Uwe Von Ahsen

Brigitte Tempelmaier

Robert Schlegl

Michael Weber

Karen Lingnau

Benjamin Wizel

Jürgen Wruss

Christoph Reinisch

Robert Seid

Christian Ruiz

Ljubomir Paucz

Ursula Schlosser

Karin Riedl

Frank Mattner

Michael Buschle

Brigitre Tempelmaier

Alexander Otava

Sandra Zinke

Helen Kirlappos

Gerd Zettlmeissl

Duc Minh Bui

The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKLKLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 &#x3bc;m.

IC31 nanoparticles

1C31 nanoparticles

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Method for identification, isolation and production of antigens to a specific pathogen

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:&#x2014;providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;screening said at least one expression library with said antibody preparation,&#x2014;identifying antigens which bind in said screening to antibodies in said antibody preparation,&#x2014;screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and&#x2014;optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: &#x2014;providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, &#x2014;providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, &#x2014;screening said at least one expression library with said antibody preparation, &#x2014;identifying antigens which bind in said screening to antibodies in said antibody preparation, &#x2014;screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, &#x2014;identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and &#x2014;optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: &#x2014;providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, &#x2014;contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, &#x2014;detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

Method for isolating hepatitis C virus peptides

Growing community of inventors

Wr. Neustadt, Austria

Christoph Klade